$Genprex(GNPX)$ It is absolutely a hidden gem. I first purchased it below $3 and will hold for at least 6 years or until a buyout offer. GPX-001, or REQORSA is a combination of TUSC2 & ONCOPREX. The non-viral delivery system is the most advanced technology yet with low toxicity and NO COMPETITION. Acclaim-1 combines REQORSA with AstraZeneca's star product, Tagrisso (also the new standard treatment for Non-Small Cell Lung Cancer (NSCLC) replacing Tarceva in 2019), and was initiated a few days ago. The interim data is expected to be released very soon and the site selection of Acclaim-2 is ongoing as well. The oncology part will lead Genprex to at least $200. More excitingly, updates of GPX-002 will be heard soon and the first-ever gene therapy tested in humans for diabetes might be possible later next year. Before that, I expect the FDA will grant the Fast-Track Designation to GPX-002 in 2022. If successful, the diabetes part will add $300 more to the stock price. My price target for GNPX in 2026 is $500. We'll see.